Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9729576 | 0.82 | ACP3 (0.46) | ACP3 | |
| SCHEMBL3907301 | 0.81 | CYP19A1 (0.41) | ACP3NFE2L2GAAMAPK3MAPK1 | |
| SCHEMBL6189080 | 0.81 | KMO (0.36) | — | |
| SCHEMBL7502772 | 0.80 | PNMT (0.42) | ACP3KCNA5 | |
| SCHEMBL6510115 | 0.79 | MAPK14 (0.34) | CTSAMAPK1 | |
| SCHEMBL6189088 | 0.78 | PTGDR2 (0.36) | MAPK1CYP19A1 | |
| SCHEMBL1515745 | 0.77 | ACP3 (0.50) | ACP3 | |
| SCHEMBL21778081 | 0.76 | ACP3 (0.41) | ACP3 | |
| SCHEMBL11152058 | 0.76 | ACP3 (0.41) | ACP3 | |
| SCHEMBL6501170 | 0.76 | CYP19A1 (0.46) | KCNA5NFE2L2GAACYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | ACP3 61/4885KCNA5 3736/4885NFE2L2 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.